Nurix Therapeutics (NRIX) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $1.69B
- As of Nov 13, 2026
- P/E
- 5.73x
- Trailing twelve months
- P/B
- 1.74x
- Latest reported equity
- P/S
- 2.40x
- Trailing twelve months
- ROE
- 30.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $1.69B
- As of Nov 13, 2026
- P/E
- 5.73x
- Trailing twelve months
- P/B
- 1.74x
- Latest reported equity
- P/S
- 2.40x
- Trailing twelve months
- ROE
- 30.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
5.73x
P/B
1.74x
P/S
2.40x
Earnings and dividend metrics▾
Earnings
EPS
$2.70
Earnings per share
BPS
$8.88
Book value per share
ROE
30.4%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.70 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $8.88 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 30.4%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJun–Aug 2026(FY2026 Q3)
Revenue increased 8,312.5% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $8M+8,312.5%
$13M
Jun–Aug '24
$8M
Jun–Aug '25
$673M
Jun–Aug '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jun–Aug 2026 are from the 10-Q submitted to SEC EDGAR on Oct 13, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 8,312.5% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Oct 13, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- van Houte HansChief Financial Officer · Nov 4, 2026Open-market sale4,769 shares · $75KAvg. price $15.6348
Show 2 price lots
- 3,300 shares × $15.3824$51K
- 1,469 shares × $16.2018$24K
- Ring ChristineChief Legal Officer · Nov 3, 2026Open-market sale6,113 shares · $158KAvg. price $25.83294,406 shares held after
- Ring ChristineChief Legal Officer · Nov 2, 2026Open-market sale10,602 shares · $274KAvg. price $25.843
Show 2 price lots
- 9,527 shares × $25.7392$245K
- 1,075 shares × $26.7628$29K
- Hansen GwennChief Scientific Officer · Nov 2, 2026Open-market sale1,452 shares · $39KAvg. price $26.8123,452 shares held after
- Ring ChristineChief Legal Officer · Nov 2, 2026Option exercise5,786 shares · $50KAvg. price $8.7221,121 shares held after
- Hansen GwennChief Scientific Officer · Nov 2, 2026Option exercise1,452 shares · $3KAvg. price $1.86124,904 shares held after
- Hansen GwennChief Scientific Officer · Oct 30, 2026Open-market sale3,957 shares · $104KAvg. price $26.2791123,452 shares held after
- Ring ChristineChief Legal Officer · Oct 30, 2026Open-market sale3,957 shares · $104KAvg. price $26.279115,335 shares held after
- van Houte HansChief Financial Officer · Oct 30, 2026Open-market sale2,834 shares · $74KAvg. price $26.279147,514 shares held after
- van Houte HansChief Financial Officer · Oct 30, 2026Option exercise10,182 shares · $0Avg. price $0
Show 3 price lots
- 2,859 shares × $0$0
- 3,573 shares × $0$0
- 3,750 shares × $0$0
- Hansen GwennChief Scientific Officer · Oct 30, 2026Option exercise10,182 shares · $0Avg. price $0
Show 3 price lots
- 3,573 shares × $0$0
- 2,859 shares × $0$0
- 3,750 shares × $0$0
- Ring ChristineChief Legal Officer · Oct 30, 2026Option exercise10,182 shares · $0Avg. price $0
Show 3 price lots
- 3,573 shares × $0$0
- 2,859 shares × $0$0
- 3,750 shares × $0$0
- Hansen GwennChief Scientific Officer · Oct 15, 2026Open-market sale1,452 shares · $36KAvg. price $25117,227 shares held after
- Hansen GwennChief Scientific Officer · Oct 15, 2026Option exercise1,452 shares · $3KAvg. price $1.86118,679 shares held after
- GREGORY JULIA PDirector · Oct 14, 2026Open-market sale22,583 shares · $529KAvg. price $23.403810,750 shares held after
- GREGORY JULIA PDirector · Oct 14, 2026Option exercise22,583 shares · $42KAvg. price $1.8633,333 shares held after
- Ring ChristineChief Legal Officer · Oct 2, 2026Open-market sale5,786 shares · $134KAvg. price $23.18519,110 shares held after
- Ring ChristineChief Legal Officer · Oct 2, 2026Option exercise5,786 shares · $50KAvg. price $8.7214,896 shares held after
- Ring ChristineChief Legal Officer · Sep 2, 2026Open-market sale5,787 shares · $149KAvg. price $25.7599
Show 2 price lots
- 5,387 shares × $25.6947$138K
- 400 shares × $26.6375$11K
- Ring ChristineChief Legal Officer · Sep 2, 2026Option exercise5,787 shares · $50KAvg. price $8.7214,897 shares held after
- Hansen GwennChief Scientific Officer · Sep 1, 2026Open-market sale1,452 shares · $37KAvg. price $25.47117,227 shares held after
- Hansen GwennChief Scientific Officer · Sep 1, 2026Option exercise1,452 shares · $3KAvg. price $1.86118,679 shares held after
- Hansen GwennChief Scientific Officer · Aug 5, 2026Open-market sale4,356 shares · $109KAvg. price $25117,227 shares held after
- Hansen GwennChief Scientific Officer · Aug 5, 2026Option exercise4,356 shares · $8KAvg. price $1.86121,583 shares held after
- van Houte HansChief Financial Officer · Aug 4, 2026Open-market sale4,761 shares · $116KAvg. price $24.3624
Show 2 price lots
- 2,967 shares × $24.6474$73K
- 1,794 shares × $23.8911$43K
- Hansen GwennChief Scientific Officer · Aug 4, 2026Open-market sale4,111 shares · $100KAvg. price $24.3594
Show 2 price lots
- 2,611 shares × $24.6415$64K
- 1,500 shares × $23.8684$36K
- Ring ChristineChief Legal Officer · Aug 3, 2026Open-market sale16,589 shares · $382KAvg. price $23.04899,110 shares held after
- Ring ChristineChief Legal Officer · Aug 3, 2026Option exercise5,787 shares · $50KAvg. price $8.7225,699 shares held after
- Ring ChristineChief Legal Officer · Jul 30, 2026Open-market sale3,847 shares · $90KAvg. price $23.382819,912 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Nurix Therapeutics (NRIX) stock information
NASDAQ
Nurix Therapeutics (NRIX) is listed on NASDAQ. Its market capitalization is about $1.7B. On trailing-twelve-month earnings the P/E ratio is 5.73, and the P/B ratio is 1.74. Return on equity is 30.4%. These figures are computed in-house from official filings and are reference information only.
Nurix Therapeutics — frequently asked questions
- What is the P/E ratio of Nurix Therapeutics (NRIX)?
- On a trailing-twelve-month basis, NRIX trades at a P/E ratio of 5.73. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Nurix Therapeutics?
- NRIX has a market capitalization of about $1.7B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.